Detalhe da pesquisa
1.
Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.
Cell
; 184(25): 6022-6036.e18, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838159
2.
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Cell
; 181(7): 1489-1501.e15, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32473127
3.
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
Cell
; 183(4): 996-1012.e19, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010815
4.
Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses.
Nat Immunol
; 23(6): 960-970, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654851
5.
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease.
Immunity
; 56(3): 669-686.e7, 2023 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36889306
6.
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
PLoS Pathog
; 20(4): e1011680, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635853
7.
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.
Immunity
; 47(5): 990-1003.e9, 2017 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29166592
8.
Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies.
PLoS Pathog
; 19(6): e1011416, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37384622
9.
A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters.
Proc Natl Acad Sci U S A
; 119(39): e2204624119, 2022 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36074824
10.
Characterization of treatment resistance and viral kinetics in the setting of single- versus dual-active monoclonal antibodies against SARS-CoV-2.
J Infect Dis
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38716969
11.
Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
EMBO J
; 39(21): e106057, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32944968
12.
A Camptothetin Analog, Topotecan, Promotes HIV Latency via Interference with HIV Transcription and RNA Splicing.
J Virol
; 97(2): e0163022, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36719238
13.
Occult hepatitis B virus infection and current perspectives on global WHO 2030 eradication.
J Viral Hepat
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578122
14.
Managing HIV During the COVID-19 Pandemic: A Study of Help-Seeking Behaviors on a Social Media Forum.
AIDS Behav
; 28(4): 1166-1172, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37479919
15.
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
Ann Intern Med
; 176(3): 348-354, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36802755
16.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Ann Intern Med
; 176(5): 658-666, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068272
17.
Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection.
J Med Internet Res
; 26: e52499, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38696245
18.
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
J Infect Dis
; 228(Suppl 2): S77-S82, 2023 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37650231
19.
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
J Infect Dis
; 228(Suppl 2): S92-S100, 2023 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37650234
20.
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.
J Infect Dis
; 228(Suppl 2): S83-S91, 2023 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37650237